TP53 and neoplasm: On the other hand, the slightly less proliferative Trp53(R172H/R172H) tumours (Supplementary Fig. 2a, Table f) provoked a greater immune response at 12 weeks, which was dominated by CD4+ T cells (Fig. 4c–e).